Tracking Cathie Wood: ARK significantly adds over 220,000 shares of Circle while continuing to reduce positions in the genomics and healthcare sector

U.S. stocks extended their upward momentum on Tuesday. The S&P 500 rose 0.38% to close at 7,543.59, while the Nasdaq performed even stronger, gaining 0.90% to close at 26,107.01. The Dow Jones Industrial Average edged up 0.02% to finish at 52,508.27. Tech stocks continued to attract capital inflows, providing sustained momentum to the market.

On the same day, Cathie Wood significantly increased holdings in blockchain infrastructure and nuclear energy stocks, while adjusting positions in certain genetic testing companies.

Buying Focus: Blockchain Infrastructure and Clean Energy

ARK’s largest position addition this time$Circle (CRCL.US)$Over 220,000 shares—this issuer of the USDC stablecoin is benefiting from structural growth in the digital currency market. As institutional adoption continues to rise, Circle's moat as a blockchain financial infrastructure provider is becoming increasingly evident.

In the nuclear energy space,$X-Energy (XE.US)$received an addition of over 150,000 shares, reflecting ARK’s long-term bullish outlook on small modular reactor (SMR) technology. Amid surging AI computing power demand, clean and reliable nuclear energy solutions could become a key power source for data centers.

Notably,$Securitize (SECZ.US)$、$Kodiak AI (KDK.US)$Emerging names also saw significant buying, indicating ARK’s forward-looking positioning in Web3 and AI-powered embodied intelligence. In the precision medicine space,$Prime Medicine (PRME.US)$、$Ionis Pharmaceuticals (IONS.US)$gene therapy companies also received additional purchases, demonstrating firm confidence in the long-term value of precision medicine.

Simultaneously added to positions in $Pony AI (PONY.US)$ Over 17,500 shares and $WeRide (WRD.US)$ nearly 10,000 shares—these two L4 autonomous driving leaders are actively advancing the global deployment of Robotaxis.

Selling direction: Rebalancing positions in genetic testing names

The selling focus is primarily on genetic testing and biotech sectors, with$Personalis (PSNL.US)$a reduction of over 160,000 shares,$10x Genomics (TXG.US)$and a reduction of over 150,000 shares, possibly reflecting ARK’s reassessment of valuations in this sub-sector.

$Robinhood (HOOD.US)$a reduction of over 27,700 shares, potentially related to a cyclical adjustment in the fintech segment, while$Roku Inc (ROKU.US)$、$Advanced Micro Devices (AMD.US)$reductions in consumer tech and semiconductor names may aim to free up capital for allocation into emerging sectors with higher growth potential.

This round of adjustments reflects ARK’s balanced investment strategy—maintaining its core commitment to disruptive innovation while moderately managing liquidity and diversifying risk.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

203K Views